ImmunoCellular Therapeutics' ICT-107 Named One of the 100 Great Investigational Drugs for 2011
March 31, 2011
LOS ANGELES, CA - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that ICT-107 was selected by R&D Directions editors for the magazine's 10th annual list of "100 Great Investigational Drugs" featured as the cover article in the March 2011 issue. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme(GBM). Editors selected compounds that "show particular promise in a major or growing therapeutic area of unmet medical need, are actively in development, and target disease pathways using a distinctly innovative mechanism of action."
"We are excited with the early promise ICT-107 has demonstrated in extending both progression-free and overall survival in patients with GBM, with no serious adverse events reported to date," said Manish Singh, Ph.D. President and CEO. "We are pleased with the recognition from R&D Directions of ICT-107 as one of the great investigational drugs."
The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma multiforme(GBM).
In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who received the vaccine in addition to the standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent. This compares favorably with historical 61.1 percent one-year and 26.5 percent two-year survival based on the standard of care alone.
The 12-month disease-free survival from the time of surgery was 75 percent with ICT-107, compared with the historical control of 26.9 percent, and the 24 month disease-free survival with ICT-107 was 43.8 percent, compared with 10.7 percent historically. The median progression-free survival (PFS) of 16.9 months after surgery compared especially favorably with the historical median PFS of 6.9 months observed with the standard treatment. Safety data for ICT-107 also compared favorably to current treatments: no serious adverse events were reported and minor side effects included fatigue, skin rash and pruritis.
R&D Directions is a leading publication for the pharmaceutical industry and is focused on the progress of drugs advancing through research and development.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd.
Source: ImmunoCellular Therapeutics, Ltd.